论文部分内容阅读
目的探讨胺碘酮、厄贝沙坦、阿托伐他汀联合治疗原发性高血压伴阵发性心房颤动的临床疗效。方法将78例原发性高血压伴阵发性心房颤动随机分为胺碘酮+厄贝沙坦+阿托伐他汀组(A组)、胺碘酮+美托洛尔组(B组),每组39例,随访1a。比较2组治疗后血压、窦性心律维持率以及治疗前、治疗后12个月的左心房内径。结果在维持窦律方面A组优于B组,差异有统计学意义(P<0.05)。抑制左房扩大方面,A组优于B组,差异有统计学意义(P<0.05)。结论胺碘酮、厄贝沙坦、阿托伐他汀联合治疗原发性高血压伴阵发性心房颤动,可以更有效地减少房颤的复发,抑制左房扩大,值得临床推广应用。
Objective To investigate the clinical effects of amiodarone, irbesartan and atorvastatin in the treatment of patients with essential hypertension complicated with paroxysmal atrial fibrillation. Methods 78 cases of essential hypertension with paroxysmal atrial fibrillation were randomly divided into amiodarone + irbesartan + atorvastatin group (group A), amiodarone + metoprolol group (group B) , Each group 39 cases, follow-up 1a. After treatment, blood pressure, sinus rhythm maintenance rate, and left atrial diameter of 12 months after treatment were compared between the two groups. Results The group A was better than the group B in maintaining sinus rhythm, the difference was statistically significant (P <0.05). The inhibition of left atrial enlargement was better in group A than in group B, with a significant difference (P <0.05). Conclusions Combination of amiodarone, irbesartan and atorvastatin in the treatment of essential hypertension complicated with paroxysmal atrial fibrillation can effectively reduce the recurrence of atrial fibrillation and inhibit the enlargement of left atrium, which is worthy of clinical application.